Burn - Market Insights, Competitive Landscape, and Market Forecast - 2032

Burn Market by Product Type (Dressing, Medications, Devices, and Others), Type (1st Degree, 2nd Degree, 3rd Degree, and 4th degree), End-User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the growing cases of burn globally and the increasing product development and launches activities by key players.

The burn market was valued at USD 2.75 billion in 2024, growing at a CAGR of 6.27% during the forecast period from 2025 to 2032 to reach USD 4.46 billion by 2032. The demand for burn treatment is witnessing significant growth, primarily driven by the rising incidence of burn caused by chemical exposure, heat, radiation, and other sources. This surge in cases has heightened the need for effective and timely burn care solutions. Additionally, increasing awareness of advanced wound care options such as skin grafts, biological dressings, and regenerative therapies is further fueling market expansion. Complementing these trends, leading companies are actively investing in research and development, resulting in a growing number of product innovations and launches aimed at improving burn treatment outcomes. Collectively, these factors are expected to contribute to robust and sustained growth in the global burn care market throughout the forecast period from 2025 to 2032.

Burn Market Dynamics:

According to data from the World Health Organization (2023), approximately one million people in India suffer from moderate to severe burn injuries each year. In China, a study published in Frontiers (2023), reported that chronic wounds, including chronic burn wounds, affected nearly 50 million people annually, a staggering figure that highlights the urgent need for effective and scalable wound care solutions. Similarly, in Saudi Arabia, the National Institutes of Health (2023) reported that the incidence of burn injuries ranges from 112 to 518 cases per 100,000 people annually. These injuries often result in significant tissue damage and prolonged recovery periods, making regenerative treatment options essential.

The rising number of such cases across various regions is directly contributing to increased demand for burn care solutions, including medications, dressings, debridement agents, skin grafts, and topical antimicrobials. In particular, second- and third-degree burn, which cause extensive tissue damage and carry a high risk of infection, require advanced healing technologies to manage and recover effectively. Consequently, the growing incidence of severe burn injuries is a major driver of the global burn market.

Moreover, ongoing innovation and the development of advanced wound care products are further propelling market growth. For example, in June 2023, AVITA Medical, Inc. announced that the U.S. Food and Drug Administration (FDA) had approved its premarket approval (PMA) supplement for the RECELL® System, enabling its use in the treatment of full-thickness skin defects caused by severe burn injuries. The RECELL® System utilizes the regenerative power of a patient’s skin to create Spray-On Skin™ cells, promoting faster and more effective healing. Such product advancements are playing a pivotal role in bolstering the growth of the burn care market by offering innovative, patient-centric treatment options.

However, the complications in treatment and scarring and stringent regulatory requirements for product approval, among others are some of the key constraints that may limit the growth of the burn market.

Burn Market Segment Analysis:

Burn Market by Product Type (Dressing, Medications, Devices, and Others), Type (1st Degree, 2nd Degree, 3rd Degree, and 4th Degree), End-User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the burn market, the dressing category is estimated to account for the largest market share in 2024. The growth of the dressing category is attributed to the rising incidence of burn injuries worldwide, as well as the numerous clinical advantages dressings offer in burn care and management. According to the Australian Government (2023), there were 1,471 burn-related hospital admissions in Australia in 2022. Similarly, data from NHS England (2023) showed that over 250,000 people sustain burn injuries annually in the United Kingdom. These moderate to severe burn injuries are especially vulnerable to skin infections, fluid loss, scarring, and delayed wound healing, highlighting the need for effective burn care solutions.

Dressings play a crucial role in addressing these challenges. Second- and third-degree burn are particularly susceptible to microbial contamination, and dressings serve as a protective barrier against bacteria, viruses, and other environmental contaminants. Moreover, modern advanced dressings, such as hydrocolloids and hydrogels, help maintain a moist wound environment, which is vital for accelerating the healing process.

Additionally, non-adherent and moisture-retentive dressings reduce pain and discomfort by minimizing wound exposure and friction. For burn that lead to fluid loss and potential hypothermia, dressings aid in fluid retention and temperature regulation at the wound site. Certain dressings, such as those made from collagen or placental extracellular matrix, can also stimulate cell growth and support tissue regeneration. Furthermore, medicated dressings serve as drug delivery vehicles, offering localized treatment through the slow release of antibiotics, growth factors, or anti-inflammatory agents.

The growing demand for effective burn care is also being supported by technological advancements and product innovation by key market players. For instance, in March 2023, Convatec received FDA clearance for its InnovaBurn® placental extracellular matrix dressing, developed for the treatment of complex surgical wounds and partial-thickness second-degree burn. Designed specifically for burn and hard-to-heal wounds, InnovaBurn® leverages the regenerative properties of placental tissue to enhance wound healing and reduce complications.

Such innovations are not only improving patient outcomes but also significantly contributing to the expansion of the burn care dressings segment, positioning it as a key driver of overall burn market growth.

North America is expected to dominate the overall burn market:

North America is projected to hold the largest share of the burn market in 2024, driven by several key factors. This regional dominance is primarily attributed to the rising cases of burn in the region, with increasing awareness of advanced wound care. Additionally, advanced healthcare infrastructure and various product approvals and new launches by key market players are further fueling market growth in the region. These combined factors position North America as the leading region in the global burn market.

According to data from the National Institutes of Health (2023), approximately 500,000 people in the United States suffer from burn injuries each year. A separate NIH report from 2022 estimated that around 46,000 of these cases require hospitalization, highlighting the significant burden of moderate to severe burn in the region. To manage these injuries effectively, a wide range of burn care products, including advanced dressings, topical agents, and enzymatic debriding solutions are being applied to promote healing, prevent infections, and minimize scar formation. Therefore, the rising incidence of burn injuries is a major factor driving the growth of the burn market in North America.

This trend is further supported by continuous product approvals and commercial launches aimed at improving clinical outcomes in burn care. For instance, in September 2023, Vericel Corporation announced the U.S. commercial availability of NexoBrid® (anacaulase-bcdb) for the treatment of severe thermal burn in adults. NexoBrid is a botanical drug product containing proteolytic enzymes, specifically indicated for the removal of eschar in cases of deep partial- and full-thickness thermal burn. This enzymatic debridement option offers a less invasive alternative to surgical procedures, reducing complications and speeding up the recovery process. Such innovative product launches are playing a pivotal role in advancing burn care practices and are expected to further foster burn market growth in North America throughout the forecast period.

Therefore, the combination of a rising cases of burn injuries and ongoing product launches is expected to significantly propel the growth of the burn market in the North America from 2025 to 2032.

Burn Market Key Players:

Some of the key market players operating in the burn market include Pfizer Inc., Viatris Inc., GSK plc, Dynarex Corporation, Beiersdorf AG, Vericel Corporation, AVITA Medical, Inc., Smith+Nephew, Convatec Inc., Mölnlycke AB, Cardinal Health, Integra LifeSciences, ManukaMed, Anika Therapeutics, Inc., PolyNovo Limited, McKesson Corporation, Kerecis, Mallinckrodt Pharmaceuticals, Evonik, Cook, and others.

Recent Developmental Activities in the Burn Market:

• In August 2024, Destiny Pharma, a clinical-stage biotechnology company focused on developing novel therapies for life-threatening infections, announced that the U.S. Food and Drug Administration (FDA) had granted Qualified Infectious Disease Product (QIDP) designation to its investigational XF-73 Dermal Gel. The designation applies to the treatment or prevention of Staphylococcal infections, including MRSA, in burn wounds, highlighting the product's potential in addressing serious antimicrobial resistance challenges in burn care.
• In January 2023, Kerecis announced the release of two new products for the burn market, GraftGuide Mano™ and GraftGuide Micro™. Both products use intact fish skin to aid burn wound healing. GraftGuide Mano™ is designed specifically for burn on the hands, while GraftGuide Micro™ is a fragmented form of the product that allows it to cover large and uneven burn areas effectively.
• In December 2022, MediWound Ltd. announced that the U.S. Food and Drug Administration (FDA) approved NexoBrid® (anacaulase-bcdb) for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burn.

Key takeaways from the burn market report study

• Market size analysis for the current burn market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the burn market.
• Various opportunities available for the other competitors in the burn market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current burn market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for the burn market growth in the future?

Target audience who can benefit from this burn market report study

• Burn product providers
• Research organizations and consulting companies
• Burn-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in burn
• Various end-users who want to know more about the burn market and the latest technological developments in the burn market.

Frequently Asked Questions for the Burn Market:

1. What is burn?

• Burn refers to the medical management and treatment of burn injuries, aimed at promoting wound healing, preventing infection, minimizing pain, and reducing scarring. It involves the use of specialized dressings, medications, surgical interventions, and rehabilitation therapies to restore skin integrity and function.

2. What is the market for burn?

• The burn market was valued at USD 2.75 billion in 2024, growing at a CAGR of 6.27% during the forecast period from 2025 to 2032 to reach USD 4.46 billion by 2032.

3. What are the drivers for the burn market?

• The demand for burn is growing steadily, mainly due to the rising number of burn injuries caused by chemicals, heat, radiation, and other sources. This increase has created a greater need for effective and timely burn care solutions. At the same time, awareness of advanced treatments like skin grafts, biological dressings, and regenerative therapies is also rising, supporting market growth. In response, major companies are boosting research and launching new products to improve burn care. Together, these factors are expected to drive strong and consistent growth in the global burn care market during the forecast period from 2025 to 2032.

4. Who are the key players operating in the burn market?

• Some of the key market players operating in the burn market include Pfizer Inc., Viatris Inc., GSK plc, Dynarex Corporation, Beiersdorf AG, Vericel Corporation, AVITA Medical, Inc., Smith+Nephew, Convatec Inc., Mölnlycke AB, Cardinal Health, Integra LifeSciences, ManukaMed, Anika Therapeutics, Inc., PolyNovo Limited, McKesson Corporation, Kerecis, Mallinckrodt Pharmaceuticals, Evonik, Cook, and others.

5. Which region has the highest share in the burn market?

• North America is projected to hold the largest share of the burn market in 2024, driven by several key factors. This regional dominance is primarily attributed to the rising cases of burns in the region, with increasing awareness of advanced wound care. Additionally, advanced healthcare infrastructure and various product approvals and new launches by key market players are further fueling market growth in the region. These combined factors position North America as the leading region in the global burn market.

This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.